BRIEF-Rezolute Announces Phase 3 SunRIZE Study Results In Congenital Hyperinsulinism

Reuters12-11

Dec 11 (Reuters) - Rezolute Inc RZLT.O:

REZOLUTE INC: ANNOUNCES PHASE 3 SUNRIZE STUDY RESULTS IN CONGENITAL HYPERINSULINISM
REZOLUTE INC - PHASE 3 STUDY FAILS TO MEET PRIMARY ENDPOINT
REZOLUTE INC - SERIOUS HYPERSENSITIVITY REACTIONS IN TWO STUDY PARTICIPANTS
REZOLUTE INC: PHASE 3 UPLIFT STUDY FOR TUMOR HI IS ONGOING WITH TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2026

Source text: ID:nGNX9gKD0D

Further company coverage: RZLT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590159575?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590159575","market":"nz","top_or_hot":-1,"title":"BRIEF-Rezolute Announces Phase 3 SunRIZE Study Results In Congenital Hyperinsulinism","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rezolute Announces Phase 3 SunRIZE Study Results In Congenital Hyperinsulinism</title></head><body><p><span>Dec 11 (Reuters)</span><span> - </span>Rezolute Inc <span>RZLT.O</span>:</p><ul><li><p>REZOLUTE INC:  ANNOUNCES PHASE 3 SUNRIZE STUDY RESULTS IN CONGENITAL HYPERINSULINISM</p></li><li><p>REZOLUTE INC - PHASE 3 STUDY FAILS TO MEET PRIMARY ENDPOINT</p></li><li><p>REZOLUTE INC - SERIOUS HYPERSENSITIVITY REACTIONS IN TWO STUDY PARTICIPANTS</p></li><li><p>REZOLUTE INC: PHASE 3 UPLIFT STUDY FOR TUMOR HI IS ONGOING WITH TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNX9gKD0D</span></p><p>Further company coverage: <span>RZLT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Rezolute Announces Phase 3 SunRIZE Study Results In Congenital Hyperinsulinism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Rezolute Announces Phase 3 SunRIZE Study Results In Congenital Hyperinsulinism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rezolute Announces Phase 3 SunRIZE Study Results In Congenital Hyperinsulinism</title></head><body><p><span>Dec 11 (Reuters)</span><span> - </span>Rezolute Inc <span>RZLT.O</span>:</p><ul><li><p>REZOLUTE INC:  ANNOUNCES PHASE 3 SUNRIZE STUDY RESULTS IN CONGENITAL HYPERINSULINISM</p></li><li><p>REZOLUTE INC - PHASE 3 STUDY FAILS TO MEET PRIMARY ENDPOINT</p></li><li><p>REZOLUTE INC - SERIOUS HYPERSENSITIVITY REACTIONS IN TWO STUDY PARTICIPANTS</p></li><li><p>REZOLUTE INC: PHASE 3 UPLIFT STUDY FOR TUMOR HI IS ONGOING WITH TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNX9gKD0D</span></p><p>Further company coverage: <span>RZLT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RZLT","symbol_name":"Rezolute, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0PY:1","article_id":"2590159575","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590159575","pubTimestamp":1765457324,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Rezolute Announces Phase 3 SunRIZE Study Results In Congenital HyperinsulinismDec 11 (Reuters) - Rezolute Inc RZLT.O:REZOLUTE INC:  ANNOUNCES PHASE 3 SUNRIZE STUDY RESULTS IN CONGENITAL HYPERINS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RZLT":"Rezolute, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Rezolute宣布先天性高胰岛素血症3期SunRIZE研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RZLT":0.9},"content_text":"BRIEF-Rezolute Announces Phase 3 SunRIZE Study Results In Congenital HyperinsulinismDec 11 (Reuters) - Rezolute Inc RZLT.O:REZOLUTE INC:  ANNOUNCES PHASE 3 SUNRIZE STUDY RESULTS IN CONGENITAL HYPERINSULINISMREZOLUTE INC - PHASE 3 STUDY FAILS TO MEET PRIMARY ENDPOINTREZOLUTE INC - SERIOUS HYPERSENSITIVITY REACTIONS IN TWO STUDY PARTICIPANTSREZOLUTE INC: PHASE 3 UPLIFT STUDY FOR TUMOR HI IS ONGOING WITH TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2026Source text: ID:nGNX9gKD0DFurther company coverage: RZLT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590159575","isCrawlerRequest":true}